UroGen Pharma Ltd.
URGN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | -0.20 | -0.07 | 0.15 |
| FCF Yield | -6.11% | -8.02% | -2.74% | -5.07% |
| EV / EBITDA | -16.58 | -14.78 | -18.38 | -37.08 |
| Quality | ||||
| ROIC | -26.00% | -17.67% | -12.26% | -6.52% |
| Gross Margin | 85.34% | 88.50% | 89.94% | 90.27% |
| Cash Conversion Ratio | 1.27 | 0.80 | 0.96 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.19% | -1.16% | 10.56% | 11.99% |
| Free Cash Flow Growth | 5.00% | -206.31% | 50.53% | -16.48% |
| Safety | ||||
| Net Debt / EBITDA | -0.80 | -0.57 | 1.98 | 0.20 |
| Interest Coverage | -4.72 | -4.27 | -7.11 | -6.45 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.31 | 0.27 | 0.32 |
| Cash Conversion Cycle | -90.14 | -182.24 | 12.32 | 156.20 |